The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Nature Reviews Clinical Oncology – Third-generation EGFR tyrosine-kinase inhibitors (TKIs) are the standard-of-care first-line treatment for patients with advanced-stage EGFR-mutant NSCLC and their…